e-learning
resources
Vienna 2003
Monday 29.09.2003
Epidemiological aspects of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Economic outcomes in the United States of treating COPD with inhaled corticosteroids and long-acting β-agonists in a managed care setting
Y. M. Gagnon, D. W. Maple, A. R. Levy, J. S. Hurley, F. J. Frost, M. D. Spencer, A. H. Briggs (Vancouver, Canada; Albuquerque, United States Of America; London, Oxford, United Kingdom)
Source:
Annual Congress 2003 - Epidemiological aspects of COPD
Session:
Epidemiological aspects of COPD
Session type:
Poster Discussion
Number:
1462
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. M. Gagnon, D. W. Maple, A. R. Levy, J. S. Hurley, F. J. Frost, M. D. Spencer, A. H. Briggs (Vancouver, Canada; Albuquerque, United States Of America; London, Oxford, United Kingdom). Economic outcomes in the United States of treating COPD with inhaled corticosteroids and long-acting β-agonists in a managed care setting. Eur Respir J 2003; 22: Suppl. 45, 1462
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Prescribing patterns of inhaled corticosteroids in asthma amongst primary care physicians in Singapore
Source: Virtual Congress 2021 – Primary care organisation and epidemiology
Year: 2021
Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care
Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease
Year: 2007
De-implementing inappropriate inhaled steroids use in Dutch COPD patients in primary care
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
Asthma control among patients receiving inhaled corticosteroids in general practice in Thailand
Source: Annual Congress 2010 - Questionnaires use and psychological aspects in asthma
Year: 2010
Economic implications of treatment pathways of asthma exacerbations managed in primary care in Spain
Source: Eur Respir J 2001; 18: Suppl. 33, 235s
Year: 2001
Cost of asthma exacerbations managed in primary care in Spain
Source: Eur Respir J 2001; 18: Suppl. 33, 329s
Year: 2001
Oral corticosteroid prescription patterns in asthma care in Italy
Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies
Year: 2019
Treatment of asthma exacerbations managed in primary care in Spain
Source: Eur Respir J 2001; 18: Suppl. 33, 235s
Year: 2001
Prescription of inhaled corticosteroids for COPD in general practice in Denmark – changes after participating in an educational programme
Source: Annual Congress 2008 - Management of COPD
Year: 2008
Inappropriate overuse of inhaled corticosteroids in patients with moderate COPD in UK primary care
Source: Annual Congress 2011 - Disease management in specific primary care populations
Year: 2011
Asthma-related resource use and costs for patients prescribed inhaled corticosteroids compared to leukotriene modifiers in clinical practice
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
COPD guides and inhaled corticosteroids. Is there an adequate use in primary care?
Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care
Year: 2016
Predictors of inhaled corticosteroid therapy in COPD alone compared to COPD with concomitant asthma managed in primary care
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain
Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Year: 2018
Inhaled corticosteroids in stable COPD – international recommendations and reality in Bulgaria
Source: International Congress 2017 – COPD management
Year: 2017
SABA and ICS use among mild asthma patients in UK primary care
Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies
Year: 2019
The budesonide/formoterol inhaler as maintenance and reliever therapy in Maori asthmatics
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013
Inhaled steroids prescribing in patients with COPD in the community
Source: Eur Respir J 2001; 18: Suppl. 33, 59s
Year: 2001
Manner of treatment and costs of COPD exacerbations in secondary medical care in Poland
Source: Eur Respir J 2007; 30: Suppl. 51, 194s
Year: 2007
Reduced healthcare resource utilization in asthma patients treated with omalizumab in the clinical practice in Spain
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept